About Nagoya University Hospital

About Nagoya University Hospital

Back


Message from the Director

Thank you for visiting the homepage of Nagoya University Hospital.

Nagoya University Hospital acquired certification from Joint Commission International(JCI) in 2019 to become the first JCI accredited national university hospital and has subsequently passed another surveillance for renewal in March 2022. Our world-class quality medical care and continued patient safety has been highly commended. I believe this is a well-deserved consequence of hard work by all the hospital staff members.
We are determined to continue our efforts to improve the quality of medical care and patient safety through the cycle of Plan, Do, Check, and Action.
Nationwide regulations to put into effect the work-style reform for doctors will begin in 2024. Excessive overtime work has been taken for granted as duties of a doctor in Japan. Changing this working environment is an important issue, not only to protect the health of doctors, but ultimately to maintain quality medical care and patient safety. We can hopefully establish a truly sustainable medical care in Japan through promoting the reform, but we will need to overcome a lot of difficulties during the process, especially at the starting phase.

In the field of medical treatment, we have focused on providing our original advanced and progressive medical care. One of our activities as a Core Hospital for Cancer Genome Medical Care has been to provide the Gene Panel Test to many patients. According to the results of this test, we can connect each patient to an optimal treatment drug based on biological characteristics of individual cancer rather than organ-specific clinical trial results. This is particularly beneficial for patients with rare cancers and those in need of late line treatments for refractory cancers, for which conventional scheme of developing a new drug is not always applicable. With genomic medicine, it is possible to consider a suitable drug for the treatment of individual patients based on the genetic information. In the future, we would like to expand its application not only to cancer but also to other intractable diseases.
Furthermore, in order to treat patients with rare cancers for which there is little information, the new Rare Cancer Center is established. A telephone consultation service will be set up to provide information and referrals to the appropriate medical department and specialists in response to consultations from patients and physicians in the community. Among the activities of the Inflammatory Bowel Disease Center (IBD Center), the latest drug therapies are carried out based on highly technical endoscopic diagnosis in cooperation with the Department of Internal Medicine and Department of Surgery. Provision of the appropriate surgical treatment as needed has been further enhanced by the use of minimally invasive surgery through endoscopic and robotic approach.
In addition to these efforts, in response to the request from the local government, we treat patients with severe COVID-19 symptoms at a scale which is one of the largest for a national university hospital. We will continue to respond flexibly to threats from such infectious diseases while striving to maintain our daily practice, the need for which will continue even during the pandemic phase.

Enhanced research activities support advanced clinical treatment. Our hospital has been designated as a Core Clinic Research Hospital by the Ministry of Health, Labor and Welfare and a Center for Advancing Translational Research (CATR) by the Ministry of Education, Culture, Sports, Science. Thus, we are expected to positioned to lead innovative medical developments in Japan. With a research system that seamlessly links the results of basic research to clinical application and practical use in place and researchers who are highly motivated to pursue their research activities, promising research seeds are steadily emerging. The results of advanced research can become an option in the treatment strategy of various diseases. For example, the Children' s Cancer Center, esteemed as a top-class facility in Japan, carries out clinical research on revolutionary CAR T cell therapy to treat childhood cancer.
In addition, with the establishment of Tokai National Higher Education and Research System, collaboration between our hospital and Gifu University Hospital, including the integration of electronic medical record information, is underway. As a part of this effort, the home medical care coordination system "IIJ Electronics@Contact Book" will be utilized to promote research in preventive medicine, such as the clarification of disease risk factors and regional characteristics based on information collected from persons requiring care in Aichi and Gifu Prefectures. In response to your expectations, we will seek to even further accelerate our research activities.